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In August 2016, the World Health Organization (WHO) convened the ‘‘Eighth meeting on development of
influenza vaccines that induce broadly protective and long-lasting immune responses” to discuss the reg-
ulatory requirements and pathways for licensure of next-generation influenza vaccines, and to identify
areas where WHO can promote the development of such vaccines. Participants included approximately
120 representatives of academia, the vaccine industry, research and development funders, and regulatory
and public health agencies. They reviewed the draft WHO preferred product characteristics (PPCs) of vac-
cines that could address prioritized unmet public health needs and discussed the challenges facing the
development of such vaccines, especially for low- and middle-income countries (LMIC). They defined
the data desired by public-health decision makers globally and explored how to support the progression
of promising candidates into late-stage clinical trials and for all countries. This report highlights the
major discussions of the meeting.
 2017 World Health Organization. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction due to the cost of care and lost productivity [1]. The World1.1. Need for next-generation vaccines
Influenza causes a substantial amount of death and suffering
annually, and it is responsible for considerable economic lossesHealth Organization (WHO) has determined that ‘‘Safe and
well-tolerated influenza vaccines that prevent severe influenza ill-
ness, provide protection beyond a single year, and are suitable
for programmatic use, are needed for low- and middle-income
countries (LMICs) [2,3].” This global health need is notzation of
tein; HI,
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ment for
ian@hhs.
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ive and
2 J.R. Ortiz et al. / Vaccine xxx (2017) xxx–xxxaddressed sufficiently by current influenza vaccine products and
evidence.
Current influenza vaccines have limited duration of protection
and must be updated annually to match the rapid evolution of cir-
culating influenza viruses. This regular reformulation of influenza
vaccines addresses two challenges, ‘‘antigenic drift” and ‘‘antigenic
shift.” Antigenic drift results from mutations within viral proteins.
New vaccines that can provide broad protection against drifted
strains could decrease the need for frequent formulation change
and greatly facilitate prevention of seasonal influenza disease in
LMICs. Antigenic shift refers to major changes in the influenza type
A hemagglutinin (HA) antigen caused by reassortment between
different influenza A subtypes. This can result in viruses to which
most of the population has no protective immunity and lead to a
global pandemic. If new vaccines with broad activity against influ-
enza A were available before the emergence of an influenza pan-
demic, they could be rapidly deployed to all countries to prevent
pandemic illness or to decrease transmission within the popula-
tion. Collectively, such new vaccines are referred to as ‘‘next-
generation” vaccines.
The WHO Product Development for Vaccines Advisory Commit-
tee (PDVAC) has concluded that, ‘‘Development of improved sea-
sonal vaccines may represent lower hanging fruit in terms of
regulatory acceptability, compared to the timelines for a truly uni-
versal influenza vaccine [4].” PDVAC has noted that, ‘‘Development
of universal influenza vaccines will be challenging and protracted,”
and recommended that, ‘‘There should be a focus on the definition
of, and the collection of data to support implementation of ‘im-
proved’ seasonal [influenza]vaccines that would offer more imme-
diate impact in LMICs [5].” PDVAC also advised WHO to, ‘‘Develop
strategic public health goals and preferred product characteristics
(PPCs) for improved seasonal [influenza] vaccines and to provide
guidance on data that would be needed to establish improved per-
formance of such vaccines [5].”
In response, this meeting was convened to discuss the regula-
tory requirements and pathways for licensure of next-generation
influenza vaccines, and to identify areas where WHO can promote
the development of such vaccines. While solutions to both sea-
sonal and pandemic influenza are likely to share technologies
and delivery systems, the meeting focused on prevention of sea-
sonal influenza through routine immunization programs. The last
WHO meeting on development of next-generation influenza vacci-
nes was in 2014 [6].
1.1.1. Potential to facilitate vaccine delivery
Influenza vaccines are reformulated up to twice yearly for use in
the Northern and Southern Hemispheres [7]. Some countries, how-
ever, have more than one epidemic period per year [8] or pro-
longed circulation of influenza virus, including different influenza
types and subtypes, for many months of the year [7,9]. The produc-
tion of influenza vaccines is timed to ensure vaccine availability
before the anticipated influenza season in temperate countries,
and the expiration date is determined to prevent use of an out-
dated formulation during the subsequent influenza season [10].
There are gaps in influenza vaccine availability when a prior for-
mulation has expired and when the next formulation is not yet
available. Theoretically, disruption can be minimized with a coun-
try alternating between different hemisphere formulations of
influenza vaccine when they become available, or by extending
the vaccine expiration date 2–3 months to complete vaccination
campaigns [10].
For several reasons, protection after vaccination might not last
for more than about six months [9], leading to the suggestion that
strategies could include year-round vaccination in settings where
influenza virus circulation is perennial [10]. Such a strategy could
also potentially better respond to drifted circulating viruses withPlease cite this article in press as: Ortiz JR et al. Report on eighth WHO meeting
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[10]. Year-round vaccination programs may have the strongest
usefulness for maternal immunization, as vaccine can protect a
woman during her pregnancy when she is at high risk for influenza
morbidity and it can protect her infant for the first months of life
when influenza vaccines are not approved for use [11]. Scenarios
of year-long use of influenza vaccines introduce many complexities
in vaccine procurement, stock rotations, and waste removal. An
influenza vaccine providing longer protection after vaccination
would simplify this situation.1.1.2. Potential to increase demand and improve equity of coverage
WHO’s influenza vaccine policy recommendations aim to pro-
tect vulnerable high-risk groups against severe influenza disease
and death [1]. While many LMICs are anticipated to prioritize vac-
cines indicated for the prevention of severe influenza illness, addi-
tional considerations including maintaining a healthy work force
and the cost-effectiveness of vaccines may drive vaccine policy
decisions in high-income countries (HICs). There is a predictable
demand in some, but not all HICs, for seasonal influenza vaccines
[12]. In addition, countries want access to a vaccine to protect
against a future influenza pandemic [13,14].
A recent study [15] showed that 59% of WHO Member States
reported having an influenza vaccine policy; however, many coun-
tries and, some whole WHO regions, do not purchase and use influ-
enza vaccines for most of their populations [12]. While this could
be seen as a failure to establish a convincing value proposition
[2], there are many reasons for this serious health inequity of
access to influenza vaccines, especially in low-resource settings
[12,15]. These include competing priorities for scarce resources;
the perception, or reality, that vaccines are unaffordable; lack of
data on local burden of influenza-associated disease; logistical dif-
ficulties of vaccinating the populations at risk; availability and tim-
ing of the appropriate vaccine formulation [16] and short vaccine
shelf-life with need for annual stock replacement [10]. While com-
prehensive studies have not been conducted to determine why
low-resource countries are not adopting influenza vaccines, one
survey indicated that low recognition of influenza as a severe dis-
ease among immunization program and policy leaders may play a
role [17]. Additionally, policy makers from low-resource countries
are expected to place higher value on vaccines with demonstrated
impact on severe illness – and such data for influenza are limited,
particularly in such settings [2,3].
The unmet need for influenza vaccines in LMICs may be
addressed by using current vaccines in different ways and not just
by using novel products. Several attendees thought that vaccine
price will also remain a key consideration.
Many of the improvements in influenza vaccines would be val-
ued in both LMICs and HICs markets. This would provide a com-
mercial rationale for developing products that can be used in
both markets, even if the vaccine presentation and packaging
might be different [18]. For example, multi-dose vials are recom-
mended for LMICs due to the relatively low cost and cold-chain
storage volume per dose [19], whereas pre-filled syringe presenta-
tions are preferred in HICs due to their convenience.1.2. Unaddressed evidence needs among specific target groups
In 2012, WHO recommendations for the use of seasonal influ-
enza vaccines were published [1]. Pregnant women were listed
as the highest priority group in countries starting or expanding
their influenza vaccine programs because they have increased risk
of influenza morbidity, antenatal services in most countries could
facilitate the delivery of influenza vaccines during pregnancy,
and influenza vaccines are effective in this group [20]. Other riskon development of influenza vaccines that induce broadly protective and
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chronic conditions and healthcare workers.
In HICs, burden of influenza disease is greatest in the elderly
and in persons with chronic illness. The burden of influenza dis-
ease among risk groups, particularly adults, is not as well studied
in LMICs, however recent data suggest similar patterns of severe
influenza illness at extremes of age, but influenza mortality may
be higher in younger persons than is seen in HIC settings [21,22].
For children, more is known. In 2016, influenza was estimated to
be responsible for 1.4% of all <5 years mortality globally [23].
Others estimate that 99% of influenza mortality in this age group
occurs in LMICs [24]. A 2016 study estimates the proportion of
deaths caused by influenza is highest among those aged 1–12
months, with 2.8% of all deaths in this age group, worldwide [25].
All countries have immunization systems that can reach chil-
dren <2 years [26], however influenza vaccine effectiveness is
lower in this age group than in others pediatric age groups [1]. Fur-
ther, influenza vaccines are not currently licensed for ages less
than 6 months [10]. Improving vaccine performance in young chil-
dren and aligning vaccine licensure with pediatric vaccine sched-
ules in LMICs should be a global priority [3].2. WHO preferences for next-generation influenza vaccines
2.1. Development of WHO preferred product characteristics (PPCs) for
next-generation influenza vaccines
WHO’s PPCs are intended to encourage innovation in vaccine
development [2,3]. They describeWHO recommendations for attri-
butes of vaccines, in particular their indications, target popula-
tions, implementation strategies, and clinical data needed for
assessment of safety and efficacy. PPCs are shaped by the global
unmet public health need in a priority disease area for which
WHO encourages vaccine development. These preferences reflect
WHO’s mandate to promote the development of vaccines with high
public health impact and suitability in LMICs.
In 2016, WHO convened an advisory group of vaccine, public
health, and research experts to recommend preferred product
characteristics for next-generation influenza vaccines to be used
in LMICs. The advisory group reviewed data on influenza disease
burden, influenza vaccine performance, influenza vaccine research
and development, immunization system logistics, and program-
matic aspects of vaccine delivery. It declared that, ‘‘Safe and well-
tolerated influenza vaccines that prevent severe influenza illness, pro-
vide protection beyond a single year, and are suitable for program-
matic use, are needed for low and middle income countries,” and set
goals with five and ten-year time horizons to address the unmet
need (Table 1).
The five-year (2022) goal was designed to promote the evalua-
tion of currently available vaccines and vaccine technologies to
demonstrate product characteristics and feasibility of use that
would align with the global unmet public health need. The ten-Table 1
WHO Preferred Product Characteristics (PPCs) for next-generation influenza vaccines
five and ten year strategic goals.
Five year
goal
By 2022, greater protection against vaccine-matched or drifted
influenza strains than provided by currently prequalified non-
adjuvanted non-replicating influenza vaccines, and protection
against severe influenza for at least one year, will have been
demonstrated for seasonal influenza vaccines that are suitable
for high-risk groups in low- and middle-income countries
Ten year
goal
By 2027, influenza vaccines that have the potential to provide
protection against severe influenza A virus illness for at least
five years, and are suitable for high-risk groups in low-and
middle-income countries, will be in advanced clinical
development
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ment of new products that are aligned with the global unmet pub-
lic health need.
The rationale, development process, and draft PPC was pre-
sented at this meeting for discussion and recommendations. Sub-
sequently, two additional public consultations were held to
solicit feedback on its contents. Afterwards, the document was
revised, reviewed by the WHO PDVAC, and approved by WHO for
publication. Details of the PPC document can be found on the
WHO website [3].
2.2. Potential to meet the 5-year goal with existing vaccines
Some currently licensed live attenuated influenza vaccines
(LAIVs) and adjuvanted inactivated influenza vaccines (IIVs) have
the potential to induce broad and/or longer lasting protection
and to meet the 2022 objective of the PPC.
LAIVs are the preferred vaccine in several countries for children
older than two years [27].
The addition of adjuvants to IIV can increase the magnitude
[28–30] and breadth of immune response [31]. Seasonal IIVs for-
mulated with MF59 adjuvant are currently licensed in many coun-
tries for use in adults 65 years and over and in Canada for children
aged 6 through 23 months [32]. However, both LAIVs and adju-
vanted IIVs are restricted to age groups for which they are licensed,
and as such do not address the global unmet needs defined in the
PPC. Efforts to evaluate these products in expanded age groups rep-
resent a feasible opportunity to address LMIC needs with currently
available products.
2.3. Potential to meet the 10-year goal with novel vaccines
Most currently licensed influenza vaccines aim primarily at the
induction of strain-specific neutralizing serum antibodies to HA,
which offer only limited protection against antigenically drifted or
shifted viruses. Broadly protective vaccines that meet the 2027 goal
will require immunization strategies that result in humoral and cel-
lular immune responses directed to conserved epitopes shared by
various influenza viruses, rather than immunodominant and vari-
able epitopes that ARE affected by antigenic drift and shift [16]. This
may entail innovative approaches such as rational antigen design,
novel approaches to antigen delivery, adjuvants, and heterologous
prime-boost regimens. As noted in recent reviews of the landscape
of broadly protective or so-called ‘‘universal” influenza vaccines
[16,33–36], there are several promising candidate vaccines in pre-
clinical development. At the meeting it was noted that the success
rate of anyvaccine candidates inpreclinical or early clinical develop-
ment is very low, suggesting that the current pipeline of approxi-
mately 20 influenza vaccine candidates in the US and Europe is
likely to yield few products thatwould ultimately achieve licensure.3. Evaluation of next-generation influenza vaccines
Some of the vaccines to address the unmet global health need
for influenza vaccines will be currently licensed vaccines used in
new populations, such as children < 6 months; some will be novel
as yet unlicensed vaccines. All will require testing for safety and
efficacy in highly controlled settings and then effectiveness and
safety studies performed in larger field trials and post-marketing
surveillance.
3.1. Immunological and virological assessments
For next-generation influenza vaccines to meet the aspira-
tions of public health, especially for LMICs, a better understand-on development of influenza vaccines that induce broadly protective and
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vaccination [37], the impact of repeat vaccination, and the nat-
ure of immune responses to vaccination in different target
groups.
3.1.1. Assay development
There was much discussion about potential serological and cell-
mediated immunity (CMI) assays, such as for T cells, memory B
cells and antibody-dependent cellular cytotoxicity (ADCC) that
could be used to understand more about immune responses to
infection and vaccination.
New assays will be needed to detect antibodies to different viral
target antigens (such as M2e or the HA-stalk region) and they must
be applied to a broad range of virus strains [38]. Some assays will
need live effector cells; the improvement and standardization of
assays of ADCC was noted as a specific example [39]. These assays
could be used to study antibody decay kinetics in longitudinal
studies.
There is already a wide variety of CMI assays available but these
are not yet standardized, and there are no established CMI-based
correlates of protection (CoPs) [40]. The optimal timing of sample
collection for CMI-based assays is likely to be 7–10 days after vac-
cination [41,42], which is very different to the day 21 or 28 sample
collection typically used for serological assays.
3.1.2. Standardisation of assays
Further standardization of novel immunological assays will be
needed so that immunogenicity results are reliable and can be
compared among laboratories. This can be achieved by several
approaches: harmonization of assays, use of international stan-
dards, assessment of laboratories (proficiency testing) and
testing/re-testing by a centralized laboratory. In recent years, there
has been progress in improving the comparability of laboratory
assays through collaborative networks, such as the Consortium
for the Standardisation of Influenza Seroepidemiology (CONSISE)
[43]. Some EU-funded initiatives, such as UNISEC, FLUCOP and
EDUFLUVAC, include standardisation [44,45].
3.1.3. Correlates of protection
Haemagglutination inhibition (HI) titre has been used as a rela-
tive CoP for IIVs: an HI titre of 40 being considered to be associ-
ated with greater than 50% reduction of the risk of influenza
infection or influenza disease [46]. Next-generation vaccines will
require new biomarkers, and in particular new CoPs [37,47,48],
and will need to be assessed with new assays. The selection of
assays and CoPs will depend on vaccine type, target antigen, and,
possibly, the target human population; for example, the immune
responses and protection induced by LAIVs and IIVs are different,
but the differences cannot be explained using a range of currently
available immunologic assays. Furthermore, LAIVs behave differ-
ently in adults compared with children [48]. Consequently, new
regulatory guidelines will likely require efficacy studies for licen-
sure of novel products.
3.2. Human challenge studies
The role and value of human challenge studies in influenza vac-
cine development was discussed at the meeting [47]. In addition to
their potential value in down-selecting vaccine candidates, they
allow detailed analysis of human immune responses and can pro-
vide initial information on new CoPs that can be further investi-
gated in clinical trials [47]. However, they can be challenging to
conduct and interpret for several reasons. Human challenge stud-
ies are usually conducted in small numbers of healthy adult volun-
teers who will have varying past exposure to influenza. A limited
number of challenge viruses are available due to the time takenPlease cite this article in press as: Ortiz JR et al. Report on eighth WHO meeting
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Practices. These viruses are not truly wild-type having been cul-
tured repeatedly, with the potential for attenuation of disease-
causing ability. Care must be taken to find susceptible volunteers
for challenge trials and this may be compromised by population
immunity to circulating influenza strains. Finally, since children
will not be part of human challenge trials, results will have to take
into consideration that there will undoubtedly be differences
between adults and children in their response to the vaccine, as
has been seen with LAIVs [48].3.3. Clinical trials
3.3.1. Clinical trial design
Clinical evaluations of next-generation influenza vaccines are
likely to seek demonstration of efficacy that is not inferior to cur-
rent vaccines and evidence of clinical benefit from increased
breadth of protection and/or increased duration of immunity. Ulti-
mately, fully-powered efficacy studies to demonstrate superior
prevention of any-severity and severe influenza disease are
desired. Efficacy studies will further need to establish the magni-
tude, quality and duration of immunity in unprimed children and
in primed individuals of all ages, to understand the effect of previ-
ous exposures on protection and to discount the possibility of dis-
ease enhancement. Clinical trials spanning two to five years will be
needed to establish the surrogates (and correlates) of durable
immunity. It is unclear how long clinical trials will need to be open
in order to prove efficacy of next-generation influenza vaccines in
the face of antigenic drift that requires changing of vaccine compo-
nents under the current influenza vaccine recommendation sys-
tem. Evidence for protection against influenza B disease also
should be addressed. Post-licensure studies will be necessary to
collect evidence for protection in neonates, pregnant women, and
other special populations. Finally, vaccine developers need to
engage with regulatory authorities and the WHO early in the clin-
ical trial design process.
Primary clinical endpoints could be the prevention of laboratory
confirmed influenza disease, either mild or severe. Secondary end-
points could include efficacy against circulating viruses that are
antigenically similar to, or drifted from the vaccine antigen. Care
needs to be taken to assess possible age-shift or rebound effects,
where vaccination delays infection but the disease is more severe
if the individual is eventually infected [49].
Pivotal clinical studies with an inactive comparator could
potentially be conducted in countries in which influenza vaccines
are not yet recommended, provided that suitable clinical trial
infrastructure is available to support the trials and baseline data
are available for sample size calculations. Some developers will
carry out clinical studies only in countries where they have an
intention to market the product.
The number of subjects needed in a trial will depend on several
factors, most notably the clinical endpoint selected. With preven-
tion of mild-to-moderate disease as an endpoint, large trials will
be required [50]. These numbers were considered in the meeting
to be manageable in some settings, and are comparable with study
sizes for other infant vaccines [51]. Care must be taken with study
size calculations: one recent trial missed its pre-specified endpoint
by assuming the attack rates in the study population would be sim-
ilar for each influenza A subtype, which was not the case [52].
The use of test-negative design methodology for observational
studies has increased our understanding of influenza vaccine effec-
tiveness from one year to the next within a population [53–55]. It
also allows comparison between countries and vaccine products,
and should be useful for studies of vaccines after their
introduction.on development of influenza vaccines that induce broadly protective and
017), https://doi.org/10.1016/j.vaccine.2017.11.061
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Standardized clinical endpoints are needed for influenza vac-
cine efficacy studies against severe disease. Severe illness clinical
endpoints should be generalizable, reproducible, and feasible for
studies conducted in LMICs. Ideally, severe illness endpoints
should be validated against objective clinical outcomes. The PPC
Advisory Group has recommended the development of standard-
ized clinical endpoints for use in influenza vaccine studies, which
should include guidance on standardization of clinical data collec-
tion, a minimum dataset to be collected in trial settings, and sever-
ity of illness scales. Influenza vaccine trials with severe illness
endpoints will have to be larger than typical influenza vaccine clin-
ical efficacy studies. However, evidence of demonstrated vaccine
efficacy against severe influenza illness would be of high public
health value and would be expected to have a greater impact on
LMIC policy-making than trials designed to assess efficacy against
ambulatory illness. Further, single year studies are vulnerable to
failure due to year-to-year variability in influenza attack rates.
Studies of at least two years duration are therefore preferable to
mitigate against the risk of failure. Additional long-term studies
will also be necessary to demonstrate the duration of clinical pro-
tection, however these studies need not be part of original efficacy
trials and may be more amenable to study with observational
methods.3.3.3. Safety
Adverse events (AEs) following use of influenza vaccines can be
influenced by host factors (age, gender, hypersensitivity, genetics,
previous doses of vaccine), environmental factors (disease back-
ground, poverty), or vaccine-related factors (type, production
method, adjuvants, other components, dose, route of administra-
tion, concomitant vaccines). It is not known which components
are responsible for most AEs following influenza vaccination.
An Institute for Vaccine Safety white paper was published fol-
lowing a systematic review of the safety of influenza vaccines in
children, assessing many thousands of reports [56]. It concluded,
‘‘All vaccines intended for use in children require safety testing in
the target age group, especially in young children. Safety of one influ-
enza vaccine in children should not be extrapolated to assumed safety
of all influenza vaccines in children.”
Inclusion of pregnant women in vaccine clinical trials may be
challenging in many countries yet the benefits of protection
against influenza are well documented for pregnant women and
infants [11]. Data from pregnancy registers, (i.e. women who
become pregnant during participation in vaccine trials), or from
post-marketing reports may be accepted by regulatory authorities
as support for the use of the vaccine in this group.
If the vaccine contains a novel adjuvant, additional collection of
safety data is likely to be required as well as follow-up longer than
12 months after the last dose, which is currently required. Vaccine
developers already collect data on induction or aggravation of
potentially immune-mediated diseases (for the US Food and Drug
Administration) and AEs of special interest (for the EMA) [57],
however surveillance for these conditions is lacking in many less
developed countries.4. Regulation of novel vaccines
Evaluation of applications for regulatory approval of novel
influenza vaccines will follow standard practices with a complete
data package, and evidence to support the claims made. Regulators
may permit some extension of claims based on adequate data. For
example, a vaccine claiming longer-lasting protection might
demonstrate three years’ protection at first licensure and then
extend this to five years or more through a supplementary filing.Please cite this article in press as: Ortiz JR et al. Report on eighth WHO meeting
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dren and then further indications for the elderly, infants aged less
than six months and pregnant women. Demonstration of broad
protection in pre-clinical models will be needed to support these
claims in humans where not all strains can be tested during clinical
evaluation.
In addition, post-vaccination sera from clinical studies can be
tested against a panel of virus strains in serologic studies. In gen-
eral, as for all novel products, regulators encourage vaccine devel-
opers to speak to them early to help plan product-specific
development.
New guidelines for marketing authorization applications for
seasonal and what used to be referred to as pre-pandemic and pan-
demic vaccines have recently been published by the European
Medicines Agency (EMA) and came into effect in February 2017
[58,59]. They set a requirement to conduct randomized clinical tri-
als in young children (aged 6 months to 3 years) and place empha-
sis on the use of a post-marketing risk management plan to
monitor the benefits and risks of influenza vaccines. The guidelines
cover IIVs, LAIVs and vaccines with adjuvants, and its principles are
applicable to several approaches towards novel vaccines.5. Post-licensure studies
5.1. Safety and efficacy
As noted, post-licensure studies will be necessary to collect evi-
dence for protection in neonates, pregnant women, and other spe-
cial populations. In addition, post-introduction surveillance will be
required to detect serious AEs, which may occur at a very low rate
and not be detectable until vaccines are used widely.
5.2. Vaccine-probe studies
There was much interest in funding influenza vaccine-probe
studies in LMICs. These studies would be designed to look at the
impact of vaccine use on both influenza-specific endpoints as well
as relevant public health outcomes such as all-cause severe lower
respiratory tract infections, deaths and healthcare usage. Such
studies have been useful for demonstrating the public health value
of Haemophilus influenzae (Hib), Streptococcus pneumoniae and
rotavirus vaccines. For influenza [60] such studies could provide
data to establish the preventable burden of influenza disease and
inform vaccine introduction decisions in low-resource settings
[50,61].
For a probe study to be successful, the availability of a safe and
effective vaccine in the targeted age group is necessary. Some par-
ticipants considered that suitable vaccine(s) might already be
available for a probe study, such as IIVs with MF59 adjuvant in
young children. Some participants expressed concern that suffi-
ciently effective vaccines are not yet available, and that conducting
a probe study under this scenario would likely harm the value
proposition for routine use of influenza vaccines, as impact on
broader disease outcomes may not be demonstrated. To mitigate
this risk, it would be important to have a properly-powered,
multi-year study in which a subset of children were followed for
laboratory-confirmed influenza outcome to establish if a null result
was due to low attack rates, poor vaccine efficacy, and/or insuffi-
cient influenza-associated severe disease outcomes.6. Encouraging, funding and supporting next-generation
vaccines
The Global Vaccine Action Plan sets a goal of, ‘‘At least one vac-
cine providing broad spectrum protection against influenza A viruson development of influenza vaccines that induce broadly protective and
017), https://doi.org/10.1016/j.vaccine.2017.11.061
6 J.R. Ortiz et al. / Vaccine xxx (2017) xxx–xxxlicensed,” by 2020 [62]. Although it was judged unlikely that this
goal will be met, it was noted that the global health community
has an opportunity to ‘‘begin with the end in mind” and plan for
implementation of next-generation influenza vaccines, especially
in LMICs.
There was optimism that better influenza vaccines would be in
advanced clinical development within the next 10 years and
enable more equitable access and higher impact. Large, experi-
enced vaccine producers as well as smaller companies have identi-
fied and are developing next-generation influenza vaccine
candidates. In part because it is not possible to predict which vac-
cine antigens, formulation or vaccination schedule will be success-
ful, non-clinical and clinical development of the candidates will
require significant funding.
There is continuing interest and support from public sector and
non-governmental funders. Funding agencies can help at a number
of different stages of vaccine development by establishing Public-
Private Partnerships (PPPs) to accelerate development and lower
risks for pharmaceutical companies; facilitating collaborations;
developing and providing access to reagents, assays, and animal
models; supporting advanced manufacturing; and financing
human challenge studies and clinical trials [47].
To sustain interest and inform investments, WHO and others
will need to continue to work closely with stakeholders on model-
ing vaccine demand, costs and prices, especially when several vac-
cine products with different claims are available. Vaccine
purchasers will want estimates of cost-saving in their populations
[63] as much as estimates of disease and deaths averted.7. Conclusions
The development of next-generation influenza vaccines
involves addressing issues that are specific to influenza vaccines,
most notably the antigenic shift and drift of the influenza virus,
as well as obstacles that are common to the development of many
vaccines and that have been successfully surmounted in the past.
Much can be learned from other PPPs to support vaccine devel-
opment and introduction for better access in low-resource settings.
Some of these vaccines have faced similar challenges to influenza:
malaria, Japanese encephalitis, meningitis A and dengue each have
restricted geographical risk in mainly LMIC targets; pneumococcal
vaccines require multiple, geographically specific serotypes; and
Hib-vaccine developers faced challenges in the communication of
burden of disease and required very large sample sizes for clinical
trials. WHO can play a role in supporting research and develop-
ment; communicating public-sector preferences; independently
evaluating vaccine candidates for probability of success, and com-
paring vaccines at late stages of development. At this meeting it
was agreed that it will be important to have strong, optimistic
and trusted voices to continue to advocate for public and private
funding throughout this process.
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